Speakers

Patricia Hurley

Senior Director

PPD Consulting

Pedro Campino

Global Regulatory Lead, Gene Therapy

CSL Behring

Anne Douar

Chief Development Officer

Vivet Therapeutics

Gavin Corcoran

Chief R&D Officer

Axovant Sciences

Nick Crabb

Programme Director, Scientific Affairs

NICE

Emily Culme-Seymour

Associate Director, Clinical Sciences

Sangamo Therapeutics

Andeleeb Dahy

Associate Director, Regulatory Affairs

Astellas

Marcus Droege

Global Head, RWE & Evidence

AveXis, a Novartis Company

Matthias Hebben

VP, Technology Development

Logicbio Therapeutics

Magali Taiel

VP, Clinical Development

GenSight Biologics

Cory Proctor

Director

Project Farma

Sven Kili

Principle

Sven Kili Consulting

Rune Kjeken

Scientific Director, Advanced Therapies, CAT

EMA

Mahesh Kudari

Program Leader, Clinical Development

Orchard Therapeutics

Ian McKay

Innovation Lead, Advanced Therapies

Innovate UK

Christeen Moburg

Senior Director, Patient Advocacy

Sangamo Therapeutics

Samantha Parker

SVP & Chief Patient Access Officer

Lysogene

Markus Peters

COO

Gemini Therapeutics

Annie Hubert

Senior Director, European Public Policy

Alliance for Regenerative Medicine (ARM)

Aleš Strancar

CEO

BIA Separations

Jim Thomson

Senior Manager, Market Access & Gene Therapy

Pfizer

Birgitte Volck

President, R&D

AVROBIO

Matthew Bending

Executive Director, HTA Strategy

PPD Biotech